What a balm can offer skin prone to psoriasis, and where treatment begins

Emollients reduce scale, itch and cracking and are recommended alongside treatment. They do not clear plaques, and no balm should claim to.

Psoriasis is an immune-mediated disease of the skin and often of the joints. A balm is a mixture of wax, fat and oil that sits on the surface. Those two facts set the boundary of this page: emollients have a real and guideline-recognised place in psoriasis care, and that place is supportive, not curative. Knowing exactly where the boundary runs is more useful than any ingredient list.

• Emollient: supportive care
• NICE CG153
• Salicylic acid: a medicine claim
• Koebner: do not scrub

What an emollient is actually for here

A psoriatic plaque is the visible end of a very fast epidermis. Keratinocyte turnover in a plaque is measured in days rather than the roughly four weeks of unaffected skin, and the corneocytes produced are retained rather than shed cleanly. The scale is that retained material: parakeratotic, poorly cohesive, and sitting on an epidermis whose barrier does not work properly, so water loss through a plaque is measurably higher than through nearby normal skin. The general mechanism is set out in transepidermal water loss.

Against that, an occlusive balm does four useful things and one thing that gets overstated.

• It hydrates the scale. Water is what makes retained corneocytes pliable. A hydrated scale is softer, less prone to fissuring and more likely to detach on its own during washing or dressing.
• It reduces itch. Itch is one of the most burdensome symptoms people report, and it tracks with dryness. Emollient use is a standard first response for it.
• It reduces cracking. Fissures on heels, knuckles and around joints hurt, bleed and get infected. Keeping thick scale supple is the practical way to prevent them.
• It improves what happens next. A prescribed topical applied to a thick, dry crust largely stays on the crust. Softened scale means the active reaches the skin underneath.

The overstated part is barrier repair. A balm slows water leaving the surface for as long as the film is there, a mechanism explained in occlusive, emollient and humectant and in moisturisers and the skin barrier. It does not correct the immune signalling driving the hyperproliferation, and the barrier defect in psoriasis is downstream of that signalling. When the plaque clears, it clears because the inflammation was treated.

Where emollients sit in the treatment guidance

The clearest statement of the ordering is the NICE guideline Psoriasis: assessment and management (CG153), published in 2012 and updated in 2017, which is the standard of care in the United Kingdom and a reasonable reference elsewhere. For plaque psoriasis on the trunk and limbs it recommends a potent topical corticosteroid once daily plus a vitamin D or vitamin D analogue once daily, applied at different times of day, for up to four weeks as the first-line option. If there is no improvement after eight weeks, the vitamin D analogue moves to twice daily. If that does not work, options include a potent corticosteroid twice daily for up to four weeks, or a coal tar preparation once or twice daily.

It also sets limits that are easy to miss: a potent corticosteroid should not be used continuously at any site for longer than eight weeks, a very potent one for longer than four, and there should be a break of about four weeks between courses. Emollients appear throughout as supportive care used alongside all of this, including the specific instruction to consider a preparation that removes adherent scale before applying an active treatment to the scalp.

The one genuinely open-ended entry on that table is the last one. Emollients have no potency ceiling and no treatment break, which is why generous, routine use is the part of the routine most worth getting right. Practical quantities are in how much balm to apply, and a balm is more concentrated than a prescribed cream, so it is usually used on defined areas rather than as whole-body cover.

Soften the scale. Do not remove it by force

Psoriasis exhibits the Koebner phenomenon, also called the isomorphic response: new lesions appear at sites of skin injury in skin that was previously clear. Reported frequency varies widely between studies depending on how it is defined and how it is elicited, with figures anywhere from around a tenth to well over half of people with psoriasis; a quarter is a commonly quoted middle estimate. Lesions typically appear one to three weeks after the injury.

The injuries that count are ordinary ones: scratching, picking, a pumice stone, a stiff exfoliating brush, tape stripping a plaque, an insect bite, sunburn, a tattoo, a surgical scar. This is the single most practical reason to distrust any advice that frames scale as something to be scrubbed off. Aggressive descaling can seed the next plaque exactly where you have been working.

Keratolytics: where a balm stops being a cosmetic

Salicylic acid is the classic descaling agent in psoriasis, and it is also the clearest example of the line this site keeps pointing at. In the United States the over-the-counter monograph covering psoriasis products, 21 CFR part 358 subpart H, lists salicylic acid at 1.8 to 3 percent and coal tar at 0.5 to 5 percent as the permitted actives. A product containing salicylic acid at those strengths and sold for psoriasis is an over-the-counter drug with a Drug Facts panel, not a cosmetic. In the European Union and United Kingdom, salicylic acid appears in Annex III of the Cosmetics Regulation with limits of 3.0 percent in rinse-off hair products and 2.0 percent in other products, restrictions on use in children under three, and the requirement that a purpose other than preservation is apparent from the presentation. Selling it as a treatment for plaques is a medicinal claim regardless of the concentration.

There is a second, practical problem for anyone thinking of putting a keratolytic into an anhydrous balm: these agents need water to work. Urea in particular is inert as a dry powder suspended in oil, and salicylic acid dissolves in the oil phase but behaves differently from an aqueous or alcoholic vehicle. The formulation detail is in urea and keratolytics, and the claim consequences are in cosmetic versus drug claims. Two interactions matter clinically as well: salicylic acid inactivates calcipotriol, so the two should not be applied together, and salicylic acid absorbs ultraviolet light, so it should not be on the skin before a phototherapy session.

Occlusion changes the strength of whatever is underneath

Putting an occlusive layer over a topical corticosteroid increases how much of it is absorbed. The size of the increase varies with the agent, the site and the duration, and multiples of several times up to around tenfold are cited in the pharmacology literature. That is not a trick to borrow. It is a deliberate clinical technique, used under supervision, precisely because it converts a moderate treatment into a stronger one, along with the risks that come with a stronger one: skin thinning, striae, telangiectasia, and at large surface areas suppression of the hypothalamic-pituitary-adrenal axis.

The practical rule is simple. If you use both, apply them at separate times, and if you have been told to occlude, follow those instructions rather than these. A common ordering is emollient first with time to absorb, then the active later in the day, or the reverse if that is what your prescriber specified. If nobody has told you, ask, because the answer depends on the specific product.

One vehicle does not fit every site

A tin of stiff wax and butter is a good product for a thick plaque on a shin and a poor one almost everywhere else. Psoriasis appears at sites with very different skin thickness, occlusion and absorption, and the vehicle has to follow the site.

Where a heavy balm does suit, the reference format on this site is the foot and heel balm, built for hyperkeratotic, fissure-prone soles. For scalp involvement the vehicle question is the whole question, and scalp balm covers what an oil-based product can and cannot do in hair. Around affected nails, only the periungual skin and cuticle are treatable with an emollient at all.

Fragrance, essential oils and the case for a short list

Contact allergy is not more common in psoriasis than in the general population in the way it is in atopic eczema, but the consequences of provoking irritation on an already inflamed plaque are worse, and the Koebner response means an irritant reaction is not merely uncomfortable. That is enough reason to strip a balm for this purpose down to materials with a long, dull safety record.

The case against botanical complexity is arithmetic rather than ideology. Every added essential oil brings a set of known sensitisers, typically limonene, linalool, geraniol, citral and eugenol, which oxidise on storage into stronger sensitisers than they started as, and which must be declared on an EU or UK label above 0.001 percent in a leave-on product. The detail is in fragrance allergens and essential oils in balms. None of them has any demonstrated benefit in psoriasis to weigh against that. A fragrance-free build is the default, and the fragrance-free balm shows what has to change beyond simply omitting the scent.

Sensory actives are worth naming separately. Menthol and camphor produce a cooling sensation that reads as relief from itch, and on fissured or excoriated skin they sting and can irritate. Colloidal oatmeal has better support for itch than most botanicals, though the evidence base sits mainly in atopic dermatitis rather than psoriasis. Petrolatum remains the least interesting and most reliable choice: highly refined, chemically simple, and used as the vehicle in patch testing because so few people react to it. Lanolin is an effective occlusive with a genuine, if uncommon, allergy history, which is worth knowing before using it on broken skin. If you are choosing a product rather than making one, reading a balm label and how to patch test a balm are the two practical skills.

Signs that mean stop and get seen

Some presentations are urgent, and none of them is a balm problem.

• Rapidly spreading redness covering most of the body, with shivering or feeling unwell. Erythrodermic psoriasis impairs temperature regulation and fluid balance and needs same-day assessment.
• Widespread small pustules on red skin, particularly with fever. Generalised pustular psoriasis is a dermatological emergency.
• Systemic upset: fever, rigors, feeling acutely unwell alongside a flare.
• Signs of infection in a fissure or excoriated plaque: increasing pain, spreading warmth and redness, pus, or a fever.
• Joint pain, stiffness lasting more than half an hour in the morning, or a swollen finger or toe. Psoriatic arthritis affects a substantial minority of people with psoriasis and can cause irreversible joint damage. Annual screening with a validated questionnaire such as PEST is recommended for anyone with any type of psoriasis.
• A flare that is not settling on the treatment you were given, or one that is affecting sleep, work or mood. Severity by surface area understates the burden, which is why quality-of-life measures are part of assessment.

Nothing here replaces the assessment. This page and the site's safety disclaimer both stop at the same place: if a clinician has given you instructions, those instructions come first, including instructions that contradict something written here.

What a balm can honestly be said to do

The decision rule is easy to state. Use an emollient or balm continuously, generously, and without waiting for a flare, because the comfort, itch and cracking benefits are real and there is no downside to routine use. Use it around the treatment your clinician prescribed, at a different time of day, and never as a substitute for it. Do not scrub. Do not occlude a steroid unless told to. Do not buy anything on the strength of a plaque-clearing claim.

For a maker, the labelling consequence is blunt. In the United Kingdom and European Union a cosmetic may not be presented as treating or preventing disease, and psoriasis is a disease. In the United States, claiming to treat psoriasis puts a product under the monograph at 21 CFR part 358 subpart H or makes it an unapproved new drug. What is defensible is unglamorous and accurate: rich, fragrance-free balm for very dry, rough or flaky skin; helps soften and hydrate rough patches; suitable for skin prone to cracking. The evidence stops there, and so should the copy. The parallel argument for atopic skin, where the trial evidence is much larger, is set out in balm for eczema.

Reviewed and updated 6 September 2026. Spotted an error? Tell us and we will fix and log it.